Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA)
Nephrology Dialysis Transplantation · 2025
DOI: 10.1093/ndt/gfaf033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Y K Onno Teng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (LuVaCs), Department of Internal Medicine-Nephrology Section, L…. Hauptthemen laut MEDLINE: Kidney Diseases, Nephrology, Immunosuppressive Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Renal Best Practice, European Renal Association, European Reference Network for Rare Kidney Diseases.
Abstract (Originalsprache)
A definition of ‘disease modification’ for kidney disease is long overdue. Here, we propose three key criteria for disease modification in immune-mediated glomerulonephritis and podocytopathies: minimizing disease activity, preventing loss of kidney structure and function, and reducing treatment-related toxicity. To be considered a disease-modifying anti-nephropathic drug (DMAND), a drug must fulfil all three criteria, hence the DMAND status of a drug may not be clear at the time of regulatory approval. Notably, the aspect of chronic kidney disease (CKD) in immune-mediated kidney diseases must be considered and treated separately, e.g. renin–angiotensin system inhibitor is a DMAND for the CKD aspect but not for the immune disease itself. Defining DMANDs is an ambitious goal but one that may help to set the priorities for future treatment strategies in immune-mediated kidney disease. This may mean much more rapid tapering or even avoidance of unselective, non-targeted immunosuppressive agents, which carry considerable short (teratogenicity) and long term risks (malignancies). The criteria proposed here set a high bar for ‘disease modification’ in immune-mediated kidney disease. Inevitably, this must dictate altered priorities with the focus for new therapeutic agents and strategies shifting from solely reduction of proteinuria to preservation of GFR and attenuation of decline, whilst also eliminating long-term toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (LuVaCs), Department of Internal Medicine-Nephrology Section, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Nephrology, Limassol General Hospital, State Health Services Organization, Limassol, Cyprus.
- University of Nicosia Medical School, Nicosia, Cyprus.
- Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
ORCID-Profile: Y K Onno Teng, Annette Bruchfeld, Fernando Caravaca-Fontan, Sarah M Moran, Safak Mirioglu, Kate I Stevens, Stefanie Steiger, Paola Romagnani, Hans-Joachim Anders
Förderung
- European Renal Best Practice
- European Renal Association
- European Reference Network for Rare Kidney Diseases
Zitieren
APA
Teng, Y. K. O., Frangou, E., Kronbichler, A., Bruchfeld, A., Caravaca-Fontan, F., Floege, J., Moran, S. M., Mirioglu, S., Stevens, K. I., Steiger, S., Romagnani, P., & Anders, H. J. (2025). Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA). Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf033
Vancouver
Teng YKO, Frangou E, Kronbichler A, Bruchfeld A, Caravaca-Fontan F, Floege J, et al. Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA). Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf033
BibTeX
@article{Teng2025,
author = {Teng, Y K Onno and Frangou, Eleni and Kronbichler, Andreas and Bruchfeld, Annette and Caravaca-Fontan, Fernando and Floege, Jürgen and Moran, Sarah M and Mirioglu, Safak and Stevens, Kate I and Steiger, Stefanie and Romagnani, Paola and Anders, Hans-Joachim},
title = {Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA)},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
doi = {10.1093/ndt/gfaf033}
}
EUVIMED